Back to top

Analyst Blog

Medical technologies major Stryker Corporation (SYK - Analyst Report) recently entered into a definitive agreement to buy privately-owned Surpass Medical, Ltd. for $135 million. The deal is expected to close in the fourth quarter of 2012, subject to certain terms and conditions.

Per the terms of the deal, Stryker plans to acquire Surpass through an all cash transaction of $100 million and has agreed to make an additional milestone payment of $35 million. Stryker exited the last reported second quarter of 2012 with cash and cash equivalents and marketable securities of $3,460 million.

The acquisition of Surpass is in accordance with Stryker’s strategy to expand its foothold into the fast-growing international markets via strategic acquisitions and new product launches. However, it is expected to have a neutral impact on Stryker’s 2012 earnings per share, excluding acquisition and integration-related expenses.

Headquartered in Tel Aviv, Israel, Surpass is a developer of pioneering flow diversion stents to treat brain aneurysms. Founded in 2005, the company has its manufacturing and research and development (R&D) facilities located at Miramar, Florida.

Surpass’ mainstay, the NeuroEndoGraft family of flow diverters, received CE Mark approval in August 2011 and is available in limited quantities outside the U.S. The company received Food and Drug Administration (FDA) approval to launch its pivotal Investigational Device Exemption (IDE) clinical trial in the fourth quarter of 2012.

Surpass’ unique product line will further bolster Stryker’s neurovascular business under the Neurotechnology and Spine division and its Complete Stroke Care portfolio. Earlier, in 2011, Stryker acquired the Neurovascular division of Boston Scientific Corporation (BSX - Analyst Report) as well as Concentric Medical, Inc. to build on its neurovascular offerings.

With a market-cap of $19.9 billion, Stryker is one of the world’s largest medical device companies operating in the global orthopedic market. The company is poised to grow on the back of a well-diversified product portfolio along with solid business fundamentals. However, end-market pressure in the Medsurg business and a weak orthopedic market continue to plague Stryker. Our Neutral recommendation on Stryker carries a short-term Zacks #3 Rank (Hold).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%